Dr Sabina Heinz and Victoria Allan

The liver disease non-alcoholic steatohepatitis (NASH) has become a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. The race is now to develop the first effective pharmacotherapy to treat it.